Anacor Pharma (ANAC) Misses Q1 EPS by 1c

Anacor Pharma (NASDAQ: ANAC) reported Q1 EPS of ($0.36), $0.01 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $17.54 million versus the consensus estimate of $19.53 million.

Cash, cash equivalents and investments totaled $137.9 million as of March 31, 2016, compared to $144.4 million as of December 31, 2015. Balances as of March 31, 2016 and December 31, 2015 included cash and cash equivalents of $25.0 million and $53.7 million, short-term investments of $110.6 million and $87.9 million and restricted investments of $2.2 million and $2.8 million, respectively.

“This is an exciting time for Anacor. In January 2016, we submitted our NDA for crisaborole topical ointment, 2%, to the FDA ahead of schedule. The FDA has accepted the crisaborole NDA for review with a PDUFA goal date of January 7, 2017. We believe there is a significant unmet medical need for a novel non-steroidal topical anti-inflammatory treatment option for patients suffering with mild-to-moderate atopic dermatitis, and we look forward to working with the FDA during the regulatory review process,” said Paul L. Berns, Anacor’s Chairman and Chief Executive Officer. “We believe that we are well positioned to execute our commercial strategy in support of the launch of crisaborole, if approved, in the U.S.”

For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c